Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aegleio

- PMLiVE

Novo’s Lantus rival Tresiba hits European markets

Company says its insulin degludec is a more flexible alternative to Sanofi's product

Sanofi reception

FDA to review Sanofi’s lixisenatide for diabetes

Follows drug's European approval under brand name Lyxumia earlier this month

- PMLiVE

FDA turns down Novo Nordisk’s Tresiba and Ryzodeg

Decision could delay the US launch of the diabetes drugs by two years or more

- PMLiVE

Sanofi receives EU approvals for diabetes and cancer drugs

Zaltrap and Lyxumia granted marketing authorisation by European Commission

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

- PMLiVE

Takeda gets FDA approval for alogliptin franchise in diabetes

Comprises Nesina, Oseni and Kazano

- PMLiVE

EU nod for Novo Nordisk’s Tresiba and Ryzodeg

Reduced risk of hypoglycaemia may give insulin products edge ahead of Sanofi’s Lantus

Boehringer, EFSD offer €2.5m in diabetes research grants

Application accepted up until April 1, 2013

- PMLiVE

Sanofi US joins NBA for diabetes awareness drive

Andre Iguodala, Danny Granger and Tamika Catchings sign up as ambassadors for Dribble to Stop Diabetes

Medicine adherence linked to doctor-patient communications

Patients’ trust and confidence in HCP impacts on adherence, according to US study

- PMLiVE

J&J gets FDA panel backing for canagliflozin

Moves ahead of BMS/AZ’s Forxiga in race for US approval as first in new class of diabetes drug

- PMLiVE

Novo Nordisk creates all-diabetes pro-cycling team

Team Novo Nordisk includes more than 100 cyclists, triathletes and runners with diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links